Andrew Bowser
Adjuvant IL-2 offers survival benefit in metastatic RCC
Orlando, FL-In patients with metastatic renal cell carcinoma, adjuvant interleukin-2 (IL-2) after cytoreductive nephrectomy appears to offer a superior survival benefit over nephrectomy followed by interferon alpha-2b, according to a report presented here at the American Society of Clinical Oncology annual meeting.
Endocrine disruptors may explain hypospadias increase
San Francisco - Researchers have successfully induced hypospadias in mice, an accomplishment that observers say provides more compelling evidence in support of the endocrine disruptor hypothesis as an explanation for the increase in hypospadias observed over the past 30 years.


View Results